$EXEL · EXELIXIS, INC.
Exelixis filed an 8-K disclosing that the FDA has extended the review period for its zanzalintinib NDA (metastatic colorectal cancer, in combination with atezolizumab) by three months. The extension follows Exelixis' submission of updated safety and efficacy data in response to an FDA information request, which the agency classified as a "major amendment." The new PDUFA action date is March 3, 2027.
- FDA extended the zanzalintinib NDA review period by three months, pushing the PDUFA date to March 3, 2027.
- Exelixis submitted updated safety and efficacy data in response to an FDA information request.
- The FDA classified the additional data submission as a 'major amendment,' triggering the extension.
- Zanzalintinib targets metastatic colorectal cancer in combination with atezolizumab.
- The original PDUFA date was December 3, 2026; the delay adds three months of regulatory uncertainty.
Extended-hours trading shows EXEL down ~2.93% to $55.75, indicating the market is treating the three-month FDA delay as a modest negative. The $14.44B market cap reflects significant zanzalintinib expectations, so any regulatory friction matters.
A three-month FDA delay on a major amendment for a key pipeline asset introduces regulatory risk that directly impacts Exelixis' near-term growth narrative.
FDA PDUFA extensions for major amendments are relatively uncommon and often signal that the agency needs more time to digest new clinical data. In the competitive CRC space, a three-month delay could give rivals an opening.
The FDA's classification of the supplemental data as a "major amendment" signals the new safety/efficacy information was substantive enough to reset the clock — not a routine administrative update. This introduces uncertainty about whether the data raised questions that could ultimately affect appro
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.